N. Besson

发表

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2004, Blood.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2011, Blood.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

T. Brümmendorf, E. Vellenga, H. Kantarjian, 2014, American journal of hematology.

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.

D. Cella, T. Masszi, Dong-Wook Kim, 2012, Leukemia research.

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).

M. Baccarani, H. Kantarjian, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2010 .

inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with

T. Brümmendorf, H. Kantarjian, R. Ribeiro, 2014 .

CLINICAL TRIALS AND OBSERVATIONS Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and / or nilotinib therapy failure Running head : Bosutinib in CP CML after second-generation TKIs

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2005 .

Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

J. Cortes, Jianxiang Wang, H. Khoury, 2010 .

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

T. Brümmendorf, G. Martinelli, J. Cortes, 2010 .

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.